Article Text

PDF
AB0675 First episode of chronic anterior uveitis in patients with juvenile idiopathic arthritis and relationship with administered treatments
  1. A. L. Boteanu1,
  2. M. A. Blazquez Cañamero1,
  3. C. Velazquez Arce1,
  4. C. Guillen Astete1,
  5. M. L. Gamir Gamir1
  1. 1Rheumatology, University Hospital ramon y Cajal, Madrid, Spain

Abstract

Background Chronic anterior uveitis is one of the most serious complications of juvenile idiopathic arthritis (JIA), showing an increased incidence in patients with early-onset disease, oligoarticualar, positive ANA. Biologic therapy used in the handling of JIA in the last years has greatly improved the articular prognosis; however their effectiveness in handling uveitis is still not well established, having reported new cases of uveitis during treatment with anti -TNF, especially during treatment with etanercept (ETN).

Objectives The aim of this work is to report the incidence of new cases of chronic anterior uveitis in patients who were treated with methotrexate (MTX), adalimumab (ADM) or Etanercept (ETN) for JIA.

Methods We performed a retrospective observational study of 70 patients with diagnosis of early-onset JIA with high risk of developing chronic anterior uveitis. There were recorded the new episodes of uveitis per patient. Incidence was calculated as the number of new episodes per 100 patients per year of follow-up according to the ILAR category and treatment and based exclusively on the treatment. Comparisons were made using T Student test.

Results Fifty-six (80.0%) patients were female and 14 (20.0%) males. The categories ILAR were: 42 (60.0%) Oligoarticular, 10 (14.3%) extended Oligoarticular, 15 (21.4%) poliarticular and 3 (4.3%) associated with psoriasis. The average age at diagnosis was 3.5 SD 1.6 years (median 3 years). ANA positive were found in 41 (58.6%) patients. The mean follow-up of patients was 4.44 SD 3.65 years. There were 5 new cases of uveitis during treatment (3 MTX, 2 MTX-ETN or ETN and 0 with ADM only) and 10 cases presented to debut or before starting DMARDs or biologic therapy. The incidence was 0.15 and 0.14 cases per 100 patient / year, respectively (p> 0.05, t Student test).

Conclusions The incidence of occurrence of uveitis in our series of JIA patients at high risk of uveitis is comparable to that described in the literature (22.8%) and similar between patients who received MTX as monotherapy and those who received MTX and ETN or ETN. We reported no new cases of uveitis in patients treated with ADM, although in 85% of cases ADA was recommended in patients diagnosed with uveitis, with studies that have shown that it is more effective than treating this complication with ETN. The number of cases that occurred during treatment with ETN in our series of cases is too small to infer a causal relationship, the stratification by immunological profile, time of disease, age or baseline severity of thesymptomscould influence the development of this complication. Prospective comparative studies of biological and non-biological DMARDs are needed to assess the increase or decrease in the risk of uveitis associated with JIA.

Disclosure of Interest None Declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.